Ovarian Cancer Quality Performance Indicators

Size: px
Start display at page:

Download "Ovarian Cancer Quality Performance Indicators"

Transcription

1 Ovarian Cancer Quality Performance Indicators Patients diagnosed between October 2013 and September 2016 Publication date 20 February 2018 An Official Statistics publication for Scotland

2 This is an Official Statistics Publication The Official Statistics (Scotland) Order 2008 authorises NHS National Services Scotland (the legal name being the Common Services Agency for the Scottish Health Service) to produce official statistics. All official statistics should comply with the UK Statistics Authority s Code of Practice which promotes the production and dissemination of official statistics that inform decision making. They can be formally assessed by the UK Statistics Authority s regulatory arm for National Statistics status. Find out more about the Code of Practice at: Find out more about official statistics at: 2

3 Contents Introduction... 4 Results and Commentary... 9 Case Ascertainment... 9 Overall Performance Summary Quality Performance Indicators Clinical Trials List of Tables Contact Further Information Rate this publication Appendices Appendix 1 Background information Appendix 3 Ovarian Cancer Clinical Trials Appendix 4 Publication Metadata Appendix 5 Early access details Appendix 6 ISD and Official Statistics

4 Introduction The cancer strategy Beating Cancer: Ambition and Action published in March 2016 builds on the commitment made in the Better Cancer Care plan to 'develop a work programme which will define how we will take forward quality indicators for cancer services' by further supporting a culture of continuous quality improvement in cancer care across NHSScotland. The new cancer strategy states a commitment to improving data collection to advance the quality and delivery of care for cancer patients. To achieve this, the Scottish Cancer Taskforce established the National Cancer Quality Steering Group (NCQSG), which includes responsibility for: The development of small sets (approximately indicators) of tumour specific national quality performance indicators (QPIs) as a proxy measure of quality care. Overseeing the implementation of the national governance framework that underpins the reporting of performance against these national QPIs. The QPIs have been developed collaboratively with the three Regional Cancer Networks: North of Scotland Cancer Network (NOSCAN), South East Scotland Cancer Network (SCAN), West of Scotland Cancer Network (WoSCAN), Information Services Division (ISD), and Healthcare Improvement Scotland. The QPIs are published on the Healthcare Improvement Scotland website. These indicators, used to drive quality improvement in cancer care across NHSScotland are kept under regular review; NHS Boards will be required to report against QPIs as part of a mandatory national cancer quality programme. ISD support NHS Boards in improving the quality of local data collection and reporting through the production of data validation specifications, and measurability criteria for QPIs. The current data sets are outlined on the Cancer Audit website. A rolling programme of reporting is planned across many tumour sites. National reports will include comparative reporting of performance against QPIs at NHS Board level across NHS Scotland, trend analysis and survival analysis (where applicable). This approach will help overcome existing issues relating to the reporting of small volumes in any one year. This report assesses performance against 9 Ovarian Cancer QPIs using clinical audit data relating to patients diagnosed with ovarian cancer for the period from October 2013 to September

5 Data collection and analysis Ovarian cancer QPI data for patients diagnosed between October 2013 and September 2016 were collected by NHS Boards, supported by the regional cancer networks, and then analysed against the Ovarian cancer measurability document. Aggregated analysed data were then submitted to ISD via a data collection template for collation to allow comparisons at NHS Board level. Data quality and completeness Small numbers: Where the number of cases meeting the denominator criteria for any indicator is between one and four, the percentage calculation has not been shown on any associated charts or tables. This is to avoid any unwarranted variation associated with small numbers and to minimise the risk of disclosure. Any charts or tables impacted by this are denoted with a dash (-). However, any commentary provided by NHS Boards relating to the impacted indicators will be included as a record of continuous improvement. Baseline Review: Following baseline review and year 1 publication of ovarian cancer QPIs data, some changes were made to measurability in order that the QPIs appropriately measured what they were intended to. These were positive changes and led to more focussed analysis in year 2. However, the alterations to measurability mean that year 1 and year 2 results may not be directly comparable for some QPIs. Formal Review: In order to ensure the success of the National Cancer QPIs in driving quality improvement in cancer care across NHS Scotland it is critical that the QPIs continue to be clinically relevant and focus on areas which will result in improvements to the quality of patient care. It was proposed that a formal review of all QPIs should take place following 3 years national comparative reporting, with tumour specific Regional Clinical Leads undertaking a key role in determining the need and extent of the review required. 5

6 For ovarian cancer, this review has already taken place; revised ovarian cancer QPIs for implementation from year 4 onwards will be published later in 2018, following public consultation. Any proposed changes to the QPIs as a result of this review will be noted in this report. Survival Analysis: For future tumour specific survival analyses, it has been agreed to use the Cancer Audit QPI dataset rather than the Cancer Registry dataset that has been used in the past. This should provide benefits in terms of improved accuracy and more specific and detailed analysis. Due to time limitations and availability of data in time for this release, therefore, it has been agreed to undertake ovarian cancer survival analysis at a later date. 6

7 Foreword from Ovarian Cancer Clinical Leads The three Regional Cancer Networks (North of Scotland Cancer Network (NOSCAN), South East Scotland Cancer Network (SCAN), and West of Scotland Cancer Network (WoSCAN)) aim to promote the highest standards of cancer care and equity of access to cancer services across Scotland. The development and introduction of national Quality Performance Indicators (QPIs) across Scotland represents a major step forward for patients with Ovarian Cancer. This is the first report of performance against the Ovarian Cancer QPIs at a national level and provides results from the first three years of QPI recording across the three Regional Cancer Networks. Results were discussed at the Scottish Gynaecological Cancer Networks Collaborative Meeting held in November The QPI results have shown that overall, the quality of ovarian cancer services across Scotland is good in many areas of care. For example, performance against QPIs for imaging prior to treatment (QPI 2), histo/cytological diagnosis (QPI 7(i)), surgical outcomes for patients with advanced disease having primary surgery (QPI 5) or delayed primary surgery (QPI 8(ii)) and pathological reporting (QPI 6) were very good. In other areas, improvements in service performance can be seen over the years of reporting, for example in the recording of the Risk of Malignancy Index (QPI 1) and the proportion of patients having a histological diagnosis (QPI 7(ii)). However, some challenges remain and these are outlined below: QPI 3: Treatment planned and reviewed at a multi-disciplinary team meeting. It is acknowledged that the target for this QPI is challenging as there will always be some patients who only present at time of requiring emergency surgery, or where ovarian cancer is an incidental finding of other primary treatment, neither of which will be discussed at MDT prior to treatment. Though these cases will make the target for this QPI challenging, it is considered useful in ensuring that these patients are reviewed. Performance against this indicator is similar across the country suggesting there are no concerns with the MDT processes in any specific regions or NHS Boards. QPI 7 (ii): Histological Diagnosis prior to starting neo-adjuvant chemotherapy. Over the three years of reporting, performance against this QPI has improved in both SCAN and WoSCAN, with regions confident that this QPI had resulted in an improvement in the decisions on the treatment provided for some patients. All NHS Boards are encouraged to ensure patients have a histological diagnosis prior to starting neo-adjuvant chemotherapy where possible. QPI 9: First-line Chemotherapy. This QPI has not been met in any of the regions in Scotland. It is acknowledged that some patients are not fit for chemotherapy while for some tumour types chemotherapy is not indicated. It is proposed that this QPI will be amended to 7

8 exclude patients with tumours where chemotherapy is not considered beneficial. This amendment will help focus the measurement on the correct group of patients and ongoing review of patients not meeting the QPI should be helpful in ensuring that chemotherapy treatment is given where appropriate. A Formal Review of the Ovarian Cancer QPIs is currently underway. As part of this review some amendments to the QPI definitions are being considered, some targets made more challenging and a number of new indicators are being developed which may prove more challenging for NHS Boards to meet in future years. We are confident that implementation of these new QPIs will drive further quality improvement in ovarian cancer services across NHSScotland. Dr Mary Cairns Consultant in Gynaecological Oncology NOSCAN Clinical Lead for Ovarian Cancer Dr Cameron Martin Consultant Gynaecologist SCAN Clinical Lead for Gynaecological Cancers Dr Kevin Burton Consultant Gynaecological Oncologist WoSCAN Clinical Lead for Gynaecological Cancers 8

9 Results and Commentary Case Ascertainment Case ascertainment is a measure of data quality and is calculated by comparing the number of new patients captured by the cancer audit with a five year average of the numbers recorded on the cancer registry. A five year average is used for registry data as the information is not available until sometime after the year under examination. This is due to data collection and verification processes. As the number of cases will vary each year, it is possible for case ascertainment to be over or under 100%. Therefore, the figures presented should be seen as an indication only. The average case ascertainment across Scotland in the year to March 2016 was 73.5%. It should be noted that the lower case ascertainment for ovarian cancer is due to the fact that the cancer audit dataset is restricted to patients with a diagnosis of epithelial ovarian cancer, which is just a subset of those identified with ovarian cancer in the Scottish Cancer Registry Estimated Case Ascertainment (%) 0.0 Grampian Highland Orkney Shetland Tayside Western Isles NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Forth Valley Greater Lanarkshire WoSCAN Scotland Arran Glasgow & Clyde NOSCAN SCAN WoSCAN Scotland No. of Audit Records Diagnosed in 2015/16 Average No. of Cancer Registrations: Estimated Case Ascertainme nt % 2013/ / /16 Average No. of Cancer Registrations : No. of Audit Records Diagnosed in 2013/14 No. of Audit Records Diagnosed in 2014/15 Estimated Case Ascertainment % Average No. of Cancer Registrations: Estimated Case Ascertainment % NOSCAN Grampian Highland Orkney Shetland Tayside Western Isles SCAN Borders Dumfries & Galloway Fife Lothian WoSCAN Ayrshire & Arran Forth Valley Greater Glasgow & Clyde Lanarkshire Scotland

10 Overall Performance Summary The tables below summarise the overall % performance across the country for each QPI. D by Health Board of Diagnosis S by Health Board of Surgery NOSCAN: 10

11 SCAN: D by Health Board of Diagnosis S by Health Board of Surgery D by Health Board of Diagnosis 11

12 D by Health Board of Diagnosis WoSCAN: S by Health Board of Surgery 12

13 2013/ / / / / / / / /16 Information Services Division Clinical Trials Summary Table by Scottish Cancer Research Network (SCRN) SCRN - North & East SCRN - South East SCRN - West Target not met Met or exceeded target Clinical Trials - Interventional - > 7.5% 3.0% 6.1% 4.9% 10.4% 15.0% 2.8% 14.4% 7.0% 11.0% Clinical Trials - Translational - > 15% 14.5% 9.8% 10.4% 37.9% 56.7% 38.3% 7.9% 6.0% 3.3% No data matching QPI criteria Data not shown due to small numbers 13

14 Quality Performance Indicators The following section includes a detailed summary of each of the nine ovarian cancer QPIs outlining the variation at NHS Board level. Charts are colour coded by reporting year or by network if reporting a single year. Where performance at either level is shown to fall below the target, commentary from the relevant NHS Board is included to provide context to the variation. Information in this report is shown by either Health Board of diagnosis or Health Board of surgery as noted. Further information at hospital level is available from the data tables, where applicable. QPI 1: Risk of Malignancy Index recorded in the patient notes RMI (Risk of Malignancy Index) score is used to inform the multidisciplinary team (MDT) decision regarding the need for specialist surgical intervention and is calculated after performing an ultrasound scan. Numerator: Number of patients with FIGO Stage 1 epithelial ovarian cancer having RMI score recorded in their notes prior to any definitive surgical intervention. Denominator: All patients with FIGO Stage I epithelial ovarian cancer undergoing definitive surgical intervention. Exclusions: Patients presenting for surgery as an emergency Patients who do not undergo ultrasound scan Target: 90% The percentage of patients in Scotland with FIGO Stage 1 epithelial ovarian cancer having RMI recorded prior to surgery steadily increased from 27% in 2013/14 to 72% in 2015/16. Although still below target, this is an encouraging trend. This improvement is also observed in NOSCAN over the 3 years with the network achieving 100% in year 3, although with relatively small numbers. In SCAN, the target was met in year 2 and WoSCAN shows significant improvement in year 3 but still below target. In both networks though, small numbers may be contributing to this variation. At the baseline review after year 1, it was noted that since an ultrasound scan is required to calculate RMI and that it is not relevant to undergo ultrasound if a CT scan is performed; then such patients should be excluded from this QPI. This exclusion was added from year 2 and may account for some of the improvement observed from year 1 to year 2. 14

15 100 QPI 1 - Risk of Malignancy Index (RMI I) recorded in the patient notes by Health Board of Diagnosis 90 90% Grampian Highland Orkney Shetland Tayside Western Isles NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Forth Valley Greater Lanarkshire WoSCAN Scotland Arran Glasgow & Clyde NOSCAN SCAN WoSCAN Scotland 2013/ / /16 Target 2015/16 Past % Performance NR for NR for NR for NHS Board/Region % Performance Numerator Denominator Numerator Exclusion Denominator 2013/ /15 Grampian Highland * - Orkney * * * * * Shetland * * * * * Tayside Western Isles * * NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Arran Forth Valley Greater Glasgow & Clyde Lanarkshire WoSCAN Scotland Source: Cancer audit - Data not shown due to small numbers * No data matching QPI criteria Several Boards commented that since many patients no longer undergo ultrasound, RMI cannot be calculated. This was discussed at the formal review where it was recognized that practice has changed with many patients now undergoing a CT scan instead of ultrasound. Since the RMI cannot be calculated without ultrasound imaging then this QPI may no longer be beneficial and does not influence clinical management. Clinical practice has changed and rapid turnaround to CT now in place. It has, therefore, been proposed that this QPI is archived from year 4 onwards. 15

16 Due to the small numbers involved in each year, the 3 year aggregate figures are shown below for reference. QPI 1 3 year aggregate figures NHS Board/Region % Performance Numerator Denominator Grampian Highland Orkney * * * Shetland * * * Tayside Western Isles NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Arran Forth Valley Greater Glasgow & Clyde Lanarkshire WoSCAN Scotland

17 QPI 2: Extent of disease assessed by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) prior to treatment It is necessary to fully image the pelvis and abdomen prior to starting any definitive treatment in order to establish the extent of disease and minimise unnecessary treatment. Numerator: Number of patients with epithelial ovarian cancer having a CT scan or MRI of the abdomen and pelvis carried out prior to starting treatment. Denominator: All patients with epithelial ovarian cancer. Exclusions: Patients who decline to undergo investigation. Patients presenting for surgery as an emergency. Target: 90% With the exception of NHS Shetland in year 2 (small numbers), all NHS Boards met the target in each year. Overall in Scotland, the percentage of patients with ovarian cancer having a CT or MRI scan prior to treatment was consistently above 97%. 100 QPI 2 - Extent of disease assessed by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) prior to treatment by Health Board of Diagnosis 90 90% Grampian Highland Orkney Shetland Tayside Western Isles NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Forth Valley Greater Lanarkshire WoSCAN Scotland Arran Glasgow & Clyde NOSCAN SCAN WoSCAN Scotland 2013/ / /16 Target 17

18 2015/16 Past % Performance NHS Board/Region % Performance Numerator Denominator NR for Numerator NR for Exclusion NR for Denominator 2013/ /15 Grampian Highland Orkney * * * * * Shetland Tayside Western Isles * - NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Arran Forth Valley Greater Glasgow & Clyde Lanarkshire WoSCAN Scotland Source: Cancer audit - Data not shown due to small numbers * No data matching QPI criteria It was noted by several NHS Boards that some patients did not have imaging prior to treatment as cancer was not suspected pre-operatively. At the formal review, it was proposed to increase the target from 90% to 95%. This will be in place for future reporting of this indicator. 18

19 QPI 3: Treatment planned and reviewed at a multi-disciplinary team meeting Evidence suggests that patients with cancer managed by a multidisciplinary team have a better outcome. There is also evidence that the multidisciplinary management of patients increases their overall satisfaction with their care. Numerator: Number of patients with epithelial ovarian cancer discussed at the MDT before definitive treatment. Denominator: All patients with epithelial ovarian cancer Exclusions: Patients who died before first treatment. Target: 95% Overall in Scotland in 2015/16, 92% of patients with epithelial ovarian cancer were discussed at the MDT before definitive treatment. This is similar to the previous 2 years but below the 95% target. In year 3, only NHS Shetland (small numbers), NHS Tayside, NHS Fife, NHS Ayrshire & Arran and NHS Forth Valley achieved the target QPI 3 - Treatment planned and reviewed at a multi-disciplinary team meeting by Health Board of Diagnosis 95% Grampian Highland Orkney Shetland Tayside Western Isles NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Forth Valley Greater Lanarkshire WoSCAN Scotland Arran Glasgow & Clyde NOSCAN SCAN WoSCAN Scotland 2013/ / /16 Target 19

20 2015/16 Past % Performance NR for NR for NR for NHS Board/Region % Performance Numerator Denominator Numerator Exclusion Denominator 2013/ /15 Grampian Highland Orkney * * Shetland Tayside Western Isles * - NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Arran Forth Valley Greater Glasgow & Clyde Lanarkshire WoSCAN Scotland Source: Cancer audit - Data not shown due to small numbers * No data matching QPI criteria Many of the NHS Boards conducted reviews into those patients not meeting target and one of the most common reasons for patients not being discussed at the MDT prior to treatment was patients receiving emergency surgery. There was some discussion around emergency cases at the baseline review and whether these should be excluded from the QPI. However it was agreed that the tolerance in the target should cover this and the performance will continue to be monitored. In other cases across several boards, cancer was not suspected prior to surgery and therefore these patients were not discussed at MDT. 20

21 QPI 4(i): Patients with early stage disease have an adequate staging operation patients undergoing primary surgery. Stage of disease is an important prognostic factor influencing choice of therapy and quality of surgical staging is a key determinant of adjuvant chemotherapy. Numerator: Number of early stage (FIGO Stage 1) epithelial ovarian cancer patients having primary surgery involving TAH, BSO, omentectomy and washings. Denominator: All early stage (FIGO Stage 1) epithelial ovarian cancer patients undergoing primary surgery. Exclusions: Patients having fertility conserving surgery. Patients with risk of malignancy index <200 Patients presenting for emergency surgery Target: 95% In each of the 3 reporting years the target was missed at a national level and with a decreasing trend. There are relatively few patients in this cohort so caution is advised when comparing across NHS Boards. At network level, only SCAN achieved target in year QPI 4 - Patients with early stage disease have an adequate staging operation (i) by Health Board of Surgery 95% Grampian Highland Orkney Shetland Tayside Western Isles NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Forth Valley Greater Lanarkshire WoSCAN Scotland Arran Glasgow & Clyde NOSCAN SCAN WoSCAN Scotland 2013/ / /16 Target 21

22 2015/16 Past % Performance NR for NR for NR for NHS Board/Region % Performance Numerator Denominator Numerator Exclusion Denominator 2013/ /15 Grampian Highland * - Orkney * * * * * Shetland * * * * * Tayside Western Isles * * * * * NOSCAN Borders * Dumfries & Galloway Fife Lothian SCAN Ayrshire & Arran Forth Valley * * * 80.0 * Greater Glasgow & Clyde Lanarkshire WoSCAN Scotland Source: Cancer audit - Data not shown due to small numbers * No data matching QPI criteria Several NHS Boards reviewed cases and provided detailed reasons for patients not meeting the QPI, including incidental findings and co-morbidities. Due to the small numbers involved in each year, the 3 year aggregate figures are shown below for reference. QPI 4(i) 3 year aggregate figures NHS Board/Region % Performance Numerator Denominator Grampian Highland Orkney * * * Shetland * * * Tayside Western Isles * * * NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Arran Forth Valley Greater Glasgow & Clyde Lanarkshire WoSCAN Scotland

23 QPI 4(ii): Patients with early stage disease have an adequate staging operation patients operated on by a gynaecological oncologist. Stage of disease is an important prognostic factor influencing choice of therapy and quality of surgical staging is a key determinant of adjuvant chemotherapy. Patients suspected of having ovarian cancer should be operated on by a gynaecological oncologist; this has been shown to improve survival for women with ovarian cancer. Numerator: Number of early stage (FIGO Stage 1) epithelial ovarian cancer patients having primary surgery involving TAH, BSO, omentectomy and washings. Denominator: All early stage (FIGO Stage 1) epithelial ovarian cancer patients operated on by a gynaecological oncologist. Exclusions: Patients having fertility conserving surgery. Patients with risk of malignancy index <200 Patients presenting for emergency surgery Target: 95% The second part of QPI4 adds the additional specification of the primary surgery being performed by a gynaecological oncologist. This further reduces the numbers in this cohort; therefore, small numbers may be contributing to any variation at NHS Board level. At national level, however, the target was not achieved in any of the three reporting years QPI 4 - Patients with early stage disease have an adequate staging operation (ii) by Health Board of Surgery 95% Grampian Highland Orkney Shetland Tayside Western Isles NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Forth Valley Greater Lanarkshire WoSCAN Scotland Arran Glasgow & Clyde NOSCAN SCAN WoSCAN Scotland 2013/ / /16 Target 23

24 2015/16 Past % Performance NR for NR for NR for NHS Board/Region % Performance Numerator Denominator Numerator Exclusion Denominator 2013/ /15 Grampian Highland * * * * * Orkney * * * * * Shetland * * * * * Tayside * * * - * Western Isles * * * * * NOSCAN Borders * Dumfries & Galloway Fife Lothian SCAN Ayrshire & Arran * * * - * Forth Valley * * * - * Greater Glasgow & Clyde Lanarkshire * * * * * WoSCAN Scotland Source: Cancer audit - Data not shown due to small numbers * No data matching QPI criteria QPI4 was discussed at the formal review where it was proposed to remove specification (ii) and remove the RMI>200 exclusion category. Due to this, a change to the target is to be considered. Due to the small numbers involved in each year, the 3 year aggregate figures are shown below for reference. QPI 4(ii) 3 year aggregate figures NHS Board/Region % Performance Numerator Denominator Grampian Highland * * * Orkney * * * Shetland * * * Tayside Western Isles * * * NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Arran Forth Valley Greater Glasgow & Clyde Lanarkshire * * * WoSCAN Scotland

25 QPI 5(i): No macroscopic residual disease following surgery for advanced disease Improved patient outcomes are observed in patients with no visible residual disease following surgical resection. Numerator: Number of patients with advanced epithelial ovarian cancer (FIGO Stage 2 or higher) with no macroscopic residual disease following surgery. Denominator: All patients with advanced epithelial ovarian cancer (FIGO Stage 2 or higher) undergoing surgery. Exclusions: Patients with FIGO Stage 4 disease. Target: 30% In 2015/16, of the 109 patients with advanced epithelial ovarian cancer diagnosed in Scotland, 64 (59%) had no residual disease following surgery. This is the third consecutive year that the target has been achieved. At NHS Board level, it was a similar pattern with all boards achieving target in each year with the exception of NHS Tayside and NHS Ayrshire & Arran in year 3, although this is due to the small numbers involved in these boards; and NHS Lanarkshire in year 1. However, it should be noted that there was a change to the exclusion criteria after the baseline review in year 1 where patients who delayed primary surgery (following neo adjuvant therapy) were excluded. This may account for some of the differences from year 1 to year QPI 5 - No macroscopic residual disease following surgery for advanced disease (i) by Health Board of Surgery % Grampian Highland Orkney Shetland Tayside Western Isles NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Forth Valley Greater Lanarkshire WoSCAN Scotland Arran Glasgow & Clyde NOSCAN SCAN WoSCAN Scotland 2013/ / /16 Target 25

26 2015/16 Past % Performance NR for NR for NR for NHS Board/Region % Performance Numerator Denominator Numerator Exclusion Denominator 2013/ /15 Grampian Highland * Orkney * * * 1 * * Shetland * * * * * Tayside Western Isles * * * * * NOSCAN Borders Dumfries & Galloway * * * - - Fife Lothian SCAN Ayrshire & Arran Forth Valley * * * Greater Glasgow & Clyde Lanarkshire WoSCAN Scotland Source: Cancer audit - Data not shown due to small numbers * No data matching QPI criteria NHS Greater Glasgow & Clyde commented that in several cases complete cytoreduction could not be achieved and questioned whether this could be improved by having colorectal assistance. Due to this, a new process is in place for seeking colorectal input in advance of surgery where applicable. It is anticipated that this additional input will improve the performance of this QPI further. Due to the small numbers involved in each year, aggregate figures for years 2 and 3 are shown below for reference (year 1 excluded due to the change in exclusion criteria). QPI 5(i) 2 year aggregate figures NHS Board/Region % Performance Numerator Denominator Grampian Highland Orkney * * * Shetland * * * Tayside Western Isles * * * NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Arran Forth Valley Greater Glasgow & Clyde Lanarkshire WoSCAN Scotland

27 QPI 5(ii): No macroscopic residual disease following surgery for advanced disease residual disease < 1cm. Improved patient outcomes are observed in patients with no visible residual disease following surgical resection. Numerator: Number of patients with advanced epithelial ovarian cancer (FIGO Stage 2 or higher) with macroscopic residual disease < 1cm. Denominator: All patients with advanced epithelial ovarian cancer (FIGO Stage 2 or higher) undergoing surgery. Exclusions: Patients with FIGO Stage 4 disease. Target: 60% The second part of QPI5 looks at the percentage of patients with residual disease < 1cm following surgery. As with QPI 5(i), the performance at national level is above target over the 3 years. There is more variation at NHS Board level but this is largely due to the small numbers involved. 100 QPI 5 - No macroscopic residual disease following surgery for advanced disease (ii) by Health Board of Surgery % Grampian Highland Orkney Shetland Tayside Western Isles NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Forth Valley Greater Lanarkshire WoSCAN Scotland Arran Glasgow & Clyde NOSCAN SCAN WoSCAN Scotland 2013/ / /16 Target 27

28 2015/16 Past % Performance NR for NR for NR for NHS Board/Region % Performance Numerator Denominator Numerator Exclusion Denominator 2013/ /15 Grampian Highland * Orkney * * * 1 * * Shetland * * * * * Tayside Western Isles * * * * * NOSCAN Borders Dumfries & Galloway * * * - * Fife Lothian SCAN Ayrshire & Arran Forth Valley * * * Greater Glasgow & Clyde Lanarkshire WoSCAN Scotland Source: Cancer audit - Data not shown due to small numbers * No data matching QPI criteria At the formal review, it was proposed to remove specification (ii) from this QPI and focus on monitoring no residual disease as in specification (i). An increase in the target for (i) from 30% to 50% was also suggested given the consistently good performance of this QPI. A change to the exclusion criteria from stage 4 to stage 4b was also proposed. Due to the small numbers involved in each year, aggregate figures for years 2 and 3 are shown below for reference (year 1 excluded due to the change in exclusion criteria). QPI 5(ii) 2 year aggregate figures NHS Board/Region % Performance Numerator Denominator Grampian Highland Orkney * * * Shetland * * * Tayside Western Isles * * * NOSCAN Borders Dumfries & Galloway * * * Fife Lothian SCAN Ayrshire & Arran Forth Valley Greater Glasgow & Clyde Lanarkshire WoSCAN Scotland

29 QPI 6: Histopathology reports are complete and support clinical decisionmaking Histopathological reporting provides prognostic indicators which inform treatment planning for women diagnosed with epithelial ovarian cancer. Numerator: Number of patients with epithelial ovarian cancer undergoing definitive cytoreductive surgery who have a complete pathology report that contains all data items as defined by the Royal College of Pathologists. Denominator: All patients with epithelial ovarian cancer undergoing definitive cytoreductive surgery. Exclusions: No exclusions Target: 90% Overall in Scotland, there has been a decrease in the percentage of patients whose pathology report is complete from 93% in 2013/14 to 79% in 2015/16. This is largely driven by an equivalent reduction in NHS Greater Glasgow & Clyde which accounts for over 35% of all the patients in this cohort. Generally, though, performance is good across boards with NHS Grampian, NHS Tayside and NHS Lothian achieving target in each year. 100 QPI 6 - Histopathology reports are complete and support clinical decision making by Health Board of Surgery 90 90% Grampian Highland Orkney Shetland Tayside Western Isles NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Forth Valley Greater Lanarkshire WoSCAN Scotland Arran Glasgow & Clyde NOSCAN SCAN WoSCAN Scotland 2013/ / /16 Target 29

30 2015/16 Past % Performance NR for NR for NR for NHS Board/Region % Performance Numerator Denominator Numerator Exclusion Denominator 2013/ /15 Grampian Highland * * * * - Orkney * * Shetland * * * * * Tayside Western Isles * * * * * NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Arran Forth Valley * * * Greater Glasgow & Clyde Lanarkshire WoSCAN Scotland Source: Cancer audit - Data not shown due to small numbers * No data matching QPI criteria NHS Greater Glasgow & Clyde conducted a review of those patients not meeting target in year 3 and concluded that most patients had delayed surgery i.e. surgery after chemotherapy. In these cases, washings will not be done and pathology cannot stage the disease relevantly. It was, therefore, suggested that patients having delayed surgery should be excluded. Although no changes to the wording of the QPI were proposed at Formal Review, it was agreed to update the notes within the data definitions to specify that washings are not required for patients undergoing delayed primary surgery. 30

31 QPI 7(i): - Histo/cytological diagnosis prior to starting neo-adjuvant chemotherapy Before commencing neo-adjuvant cytotoxic chemotherapy, women with suspected advanced ovarian cancer should have their diagnosis confirmed by histology or by cytology if histology is not appropriate. Numerator: Number of patients having histo/cytological diagnosis of epithelial ovarian cancer recorded prior to starting chemotherapy. Denominator: All patients with epithelial ovarian cancer undergoing neo-adjuvant chemotherapy. Exclusions: Patients for whom paracentesis, image-guided biopsy or laparoscopy is considered not suitable. Target: 100% Over the 3 reporting years there were 364 patients with epithelial ovarian cancer undergoing neo-adjuvant chemotherapy. In 100% of these cases, the diagnosis was confirmed by histology or cytology prior to starting chemotherapy. 100 QPI 7 Histo/cytological diagnosis prior to starting neo-adjuvant chemotherapy (i) by Health Board of Surgery 100% Grampian Highland Orkney Shetland Tayside Western Isles NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Forth Valley Greater Lanarkshire WoSCAN Scotland Arran Glasgow & Clyde NOSCAN SCAN WoSCAN Scotland 2013/ / /16 Target 31

32 2015/16 Past % Performance NHS Board/Region % Performance Numerator Denominator NR for Numerator NR for Exclusion NR for Denominator 2013/ /15 Grampian Highland Orkney * * * * * Shetland * Tayside Western Isles * * * * - NOSCAN Borders * * Dumfries & Galloway Fife Lothian SCAN Ayrshire & Arran Forth Valley Greater Glasgow & Clyde Lanarkshire WoSCAN Scotland Source: Cancer audit - Data not shown due to small numbers * No data matching QPI criteria 32

33 QPI 7(ii): - Histo/cytological diagnosis prior to starting neo-adjuvant chemotherapy - obtained by percutaneous image-guided biopsy or laparoscopy. Before commencing neo-adjuvant cytotoxic chemotherapy, women with suspected advanced ovarian cancer should have their diagnosis confirmed by histology or by cytology if histology is not appropriate. Numerator: Number of patients who have a diagnosis of epithelial ovarian cancer confirmed by histology prior to starting chemotherapy. Denominator: All patients with epithelial ovarian cancer having histo/cytological diagnosis recorded prior to starting neo-adjuvant chemotherapy. Exclusions: No exclusions Target: 80% Specification (ii) of QPI 7 looks at the proportion of those patients having a histological diagnosis prior to starting neo-adjuvant chemotherapy with histological diagnosis obtained by percutaneous image-guided biopsy or laparoscopy. Of the 131 patients in Scotland in 2015/16 in this cohort, 113 (86%) patients had their diagnosis confirmed by histology. This is above the target of 80% and an improvement from 76% in year 1. At network level, both SCAN and WoSCAN showed a similar improving trend but conversely, NOSCAN appear to be decreasing over the same period. 100 QPI 7 Histo/cytological diagnosis prior to starting neo-adjuvant chemotherapy (ii) by Health Board of Surgery % Grampian Highland Orkney Shetland Tayside Western Isles NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Forth Valley Greater Lanarkshire WoSCAN Scotland Arran Glasgow & Clyde NOSCAN SCAN WoSCAN Scotland 2013/ / /16 Target 33

34 2015/16 Past % Performance NR for NR for NR for NHS Board/Region % Performance Numerator Denominator Numerator Exclusion Denominator 2013/ /15 Grampian Highland Orkney * * Shetland * Tayside Western Isles * * * * - NOSCAN Borders * * Dumfries & Galloway Fife Lothian SCAN Ayrshire & Arran Forth Valley Greater Glasgow & Clyde Lanarkshire WoSCAN Scotland Source: Cancer audit - Data not shown due to small numbers * No data matching QPI criteria Several NHS Boards reviewed cases and provided detailed reasons for patients not meeting the QPI, most commonly due to patients receiving cytology only when biopsy was not advised or possible. At the formal review it was proposed to remove specification (i) from this QPI and focus solely on diagnosis confirmed by histology. This will be in place for future reporting of this QPI. 34

35 QPI 8(i): Delayed primary surgery Delayed primary surgery, after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer (FIGO Stage 3c or 4), should achieve optimal cytoreduction (<1cm). Improved patient outcomes are observed in patients with no visible residual disease following surgical resection. Numerator: Number of patients with advanced epithelial ovarian cancer (FIGO Stage 3c or 4) undergoing delayed primary surgery after neo-adjuvant chemotherapy. Denominator: All patients with advanced epithelial ovarian cancer (FIGO Stage 3c or 4) having neo-adjuvant chemotherapy. Exclusions: No exclusions Target: 75% Since year 1, more than 75% of patients with advanced epithelial ovarian cancer having neoadjuvant chemotherapy had delayed primary surgery, thus achieving the target in the last 2 years. Both SCAN and WoSCAN achieved the target in each of the 3 years. However, NOSCAN have yet to meet the target despite showing a significant improvement from 25% in year 1 to 71% in year 3. There is more variation at NHS Board level but this is largely due to the small numbers involved. 100 QPI 8 - Delayed primary surgery (i) by Health Board of Diagnosis % Grampian Highland Orkney Shetland Tayside Western Isles NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Forth Valley Greater Lanarkshire WoSCAN Scotland Arran Glasgow & Clyde NOSCAN SCAN WoSCAN Scotland 2013/ / /16 Target 35

36 2015/16 Past % Performance NR for NR for NR for NHS Board/Region % Performance Numerator Denominator Numerator Exclusion Denominator 2013/ /15 Grampian Highland Orkney * * * 1 * * Shetland * * Tayside * * Western Isles * * * * * NOSCAN Borders * * Dumfries & Galloway Fife Lothian SCAN Ayrshire & Arran Forth Valley Greater Glasgow & Clyde Lanarkshire WoSCAN Scotland Source: Cancer audit - Data not shown due to small numbers * No data matching QPI criteria In NHS Lanarkshire, all patients not meeting this QPI were reviewed and valid clinical reasons were provided. A common reason - also noted by other NHS Boards (NHS Dumfries & Galloway, NHS Fife, NHS Lothian and NHS Highland) was patients being unsuitable for surgery due to disease progression while on chemotherapy. In other cases, across several NHS Boards, tumours were found to be too extensive to achieve optimal resection. Due to the small numbers involved in each year, the 3 year aggregate figures are shown below for reference. QPI 8(i) 3 year aggregate figures NHS Board/Region % Performance Numerator Denominator Grampian Highland Orkney * * * Shetland Tayside Western Isles * * * NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Arran Forth Valley Greater Glasgow & Clyde Lanarkshire WoSCAN Scotland

37 QPI 8(ii): Delayed primary surgery following neo-adjuvant chemotherapy Delayed primary surgery, after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer (FIGO Stage 3c or 4), should achieve optimal cytoreduction (<1cm). Improved patient outcomes are observed in patients with no visible residual disease following surgical resection. Numerator: Number of patients with advanced epithelial ovarian cancer (FIGO Stage 3c or 4) undergoing delayed primary surgery with residual disease <1cm. Denominator: All patients with advanced epithelial ovarian cancer (FIGO Stage 3c or 4) undergoing delayed primary surgery after neo-adjuvant chemotherapy. Exclusions: No exclusions Target: 65% Specification (ii) of QPI8 looks at the percentage of patients undergoing delayed primary surgery after neo-adjuvant chemotherapy with optimal cytoreduction (i.e. residual disease < 1cm). The target of >65% was achieved at a national level in each of the three reporting years, although there is a decreasing trend across the period. This trend is largely due to an equivalent decrease observed in WoSCAN from 94% in year 1 to 73% in year 3, although still above target. 100 QPI 8 - Delayed primary surgery (ii) by Health Board of Diagnosis % Grampian Highland Orkney Shetland Tayside Western Isles NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Forth Valley Greater Lanarkshire WoSCAN Scotland Arran Glasgow & Clyde NOSCAN SCAN WoSCAN Scotland 2013/ / /16 Target 37

38 2015/16 Past % Performance NR for NR for NR for NHS Board/Region % Performance Numerator Denominator Numerator Exclusion Denominator 2013/ /15 Grampian Highland * - Orkney * * * * * Shetland * * * * * Tayside * * Western Isles * * * * * NOSCAN Borders * * Dumfries & Galloway Fife Lothian SCAN Ayrshire & Arran Forth Valley Greater Glasgow & Clyde Lanarkshire WoSCAN Scotland Source: Cancer audit - Data not shown due to small numbers * No data matching QPI criteria All cases not meeting the target were reviewed across the NHS Boards and valid clinical reasons were provided. The formal review group proposed to change this indicator to measure no residual disease rather than <1cm. Due to the small numbers involved in each year, the 3 year aggregate figures are shown below for reference. QPI 8(ii) 3 year aggregate figures NHS Board/Region % Performance Numerator Denominator Grampian Highland Orkney * * * Shetland * * * Tayside Western Isles * * * NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Arran Forth Valley Greater Glasgow & Clyde Lanarkshire WoSCAN Scotland

39 QPI 9: First-line Chemotherapy First line chemotherapy treatment of epithelial ovarian cancer should include a platinum agent, either in combination or as a single agent. Numerator: Number of epithelial ovarian cancer patients who receive chemotherapy treatment involving either paclitaxel in combination with a platinum-based compound or carboplatin only. Denominator: All epithelial ovarian cancer patients Exclusions: Patients with low-grade serous disease. Patients with FIGO stage 1a or 1b, low grade (G1) disease. Patients with Stage 1a clear cell tumours. Patients who decline chemotherapy treatment. Target: 90% Of the 415 patients with epithelial ovarian cancer in Scotland in 2015/16, 84% (349 patients) received first line chemotherapy including a platinum agent. This is a slight improvement over the previous two years but still below the target of 90%. Excluding those Boards with small numbers, only NHS Borders and NHS Forth Valley achieved the target in year QPI 9 - First-line Chemotherapy by Health Board of Diagnosis 90 90% Grampian Highland Orkney Shetland Tayside Western Isles NOSCAN Borders Dumfries & Galloway Fife Lothian SCAN Ayrshire & Forth Valley Greater Lanarkshire WoSCAN Scotland Arran Glasgow & Clyde NOSCAN SCAN WoSCAN Scotland 2013/ / /16 Target 39

Upper GI Cancer Quality Performance Indicators

Upper GI Cancer Quality Performance Indicators Publication Report Upper GI Cancer Quality Performance Indicators Patients diagnosed during January 2013 to December 2015 Publication date 28 th March 2017 An Official Statistics Publication for Scotland

More information

Testicular Cancer Quality Performance Indicators

Testicular Cancer Quality Performance Indicators Testicular Cancer Quality Performance Indicators Patients diagnosed between October 2014 and September 2017 Publication date 28 August 2018 An Official Statistics publication for Scotland This is an Official

More information

Colorectal Cancer Quality Performance Indicators

Colorectal Cancer Quality Performance Indicators Publication Report Colorectal Cancer Quality Performance Indicators Patients diagnosed between April 2013 and March 2016 Publication date 27th June 2017 An Official Statistics Publication for Scotland

More information

Acute Leukaemia Quality Performance Indicators

Acute Leukaemia Quality Performance Indicators Acute Leukaemia Quality Performance Indicators Patients diagnosed between July 2014 and June 2017 Publication date 19 June 2018 An Official Statistics publication for Scotland This is an Official Statistics

More information

Lung Cancer Quality Performance Indicators

Lung Cancer Quality Performance Indicators Publication Report Lung Cancer Quality Performance Indicators Patients diagnosed during April 2013 to December 2015 Publication date 28 th February 2017 RESTRICTED STATISTICS Release embargoed until Tuesday

More information

Clinical Audit Data: 01 October 2015 to 30 September West of Scotland Cancer Network. Gynaecological Cancer Managed Clinical Network

Clinical Audit Data: 01 October 2015 to 30 September West of Scotland Cancer Network. Gynaecological Cancer Managed Clinical Network Gynaecological Cancer Managed Clinical Network Audit Report Ovarian Cancer Quality Performance Indicators Cervical Cancer Quality Performance Indicators Endometrial Cancer Quality Performance Indicators

More information

Audit Report. Report of the 2014 Clinical Audit Data. North, South East and West of Scotland Cancer Networks

Audit Report. Report of the 2014 Clinical Audit Data. North, South East and West of Scotland Cancer Networks North, South East and West of Scotland Cancer Networks HepatoPancreatoBiliary Cancers National Managed Clinical Network Audit Report Report of the 2014 Clinical Audit Data Professor Stephen Wigmore Consultant

More information

Audit Report Report of the 2015 Clinical Audit Data

Audit Report Report of the 2015 Clinical Audit Data North, South East and West of Scotland Cancer Networks HepatoPancreatoBiliary Cancers National Managed Clinical Network Audit Report Report of the 2015 Clinical Audit Data Professor Stephen Wigmore Consultant

More information

Activity Report April 2012 to March 2013

Activity Report April 2012 to March 2013 North, South East and West of Scotland Cancer Networks Brain/Central Nervous System Tumours National Managed Clinical Network Activity Report April 2012 to March 2013 Professor Roy Rampling Emeritus Professor

More information

Audit Report Endometrial & Cervical Cancer Quality Performance Indicators

Audit Report Endometrial & Cervical Cancer Quality Performance Indicators Gynaecological Cancer Managed Clinical Network Audit Report Endometrial & Cervical Cancer Quality Performance Indicators Clinical Audit Data: 01 October 2014 to 30 September 2015 Nadeem Siddiqui Consultant

More information

Audit Report. Cervical Cancer Quality Performance Indicators. Patients diagnosed October 2014 September Published: September 2016

Audit Report. Cervical Cancer Quality Performance Indicators. Patients diagnosed October 2014 September Published: September 2016 Gynaecology Managed Clinical Network NORTH OF SCOTLAND PLANNING GROUP Audit Report Cervical Cancer Quality Performance Indicators Patients diagnosed October 2014 September 2015 Published: September 2016

More information

Scottish Bowel Screening Programme Statistics

Scottish Bowel Screening Programme Statistics Publication Report Scottish Bowel Screening Programme Statistics For invitations between 1 November 2010 and 31 October 2012 Publication date 27 August 2013 A National Statistics Publication for Scotland

More information

Audit Report. Endometrial Cancer Quality Performance Indicators. Patients diagnosed October 2014 September Published: September 2016

Audit Report. Endometrial Cancer Quality Performance Indicators. Patients diagnosed October 2014 September Published: September 2016 Gynaecology Managed Clinical Network NORTH OF SCOTLAND PLANNING GROUP Audit Report Endometrial Cancer Quality Performance Indicators Patients diagnosed October 2014 September 2015 Published: September

More information

Activity Report April 2012 March 2013

Activity Report April 2012 March 2013 North, South East and West of Scotland Cancer Networks HepatoPancreatoBiliary Cancers National Managed Clinical Network Activity Report April 2012 March 2013 Mr Colin McKay Consultant Surgeon NMCN Clinical

More information

Audit Report. Breast Cancer Quality Performance Indicators. Patients diagnosed during Published: February 2018

Audit Report. Breast Cancer Quality Performance Indicators. Patients diagnosed during Published: February 2018 Breast Cancer Managed Clinical Network Audit Report Breast Cancer Quality Performance Indicators Patients diagnosed during 2016 Published: February 2018 Mr Douglas Brown NOSCAN Breast Cancer MCN Clinical

More information

Audit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed January December Published: November 2017

Audit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed January December Published: November 2017 Lung Cancer Managed Clinical Network Audit Report Lung Cancer Quality Performance Indicators Patients diagnosed January December 2016 Published: November 2017 Hardy Remmen NOSCAN Lung Cancer MCN Clinical

More information

Audit Report Report of the 2012 Clinical Audit Data

Audit Report Report of the 2012 Clinical Audit Data Gynaecological Cancer Managed Clinical Network Audit Report Report of the 2012 Clinical Audit Data Nadeem Siddiqui Consultant Gynaecological Oncologist MCN Clinical Lead Kevin Campbell MCN Manager Julie

More information

Activity Report April 2013 March 2014

Activity Report April 2013 March 2014 North, South East and West of Scotland Cancer Networks HepatoPancreatoBiliary Cancers National Managed Clinical Network Activity Report April 2013 March 2014 Mr Colin McKay Consultant Surgeon NMCN Clinical

More information

Audit Report. Cervical Cancer Quality Performance Indicators. Patients diagnosed October 2015 September Published: September 2017

Audit Report. Cervical Cancer Quality Performance Indicators. Patients diagnosed October 2015 September Published: September 2017 Gynaecology Managed Clinical Network Audit Report Cervical Cancer Quality Performance Indicators Patients diagnosed October 2015 September 2016 Published: September 2017 Dr Ann-Maree Kennedy MCN Clinical

More information

Scottish Cancer Taskforce: National Cancer Quality Steering Group Cancer Clinical Audit

Scottish Cancer Taskforce: National Cancer Quality Steering Group Cancer Clinical Audit Scottish Cancer Taskforce: National Cancer Quality Steering Group Cancer Clinical Audit National Cancer Clinical Audit: Baseline Survey Report (May 09) Purpose: The purpose of this paper is to provide

More information

Consultation on publication of new cancer waiting times statistics Summary Feedback Report

Consultation on publication of new cancer waiting times statistics Summary Feedback Report Consultation on publication of new cancer waiting times statistics Summary Feedback Report Information Services Division (ISD) NHS National Services Scotland March 2010 An electronic version of this document

More information

Audit Report. Breast Cancer Quality Performance Indicators. Patients diagnosed during Published: December 2015 NORTH OF SCOTLAND PLANNING GROUP

Audit Report. Breast Cancer Quality Performance Indicators. Patients diagnosed during Published: December 2015 NORTH OF SCOTLAND PLANNING GROUP NORTH OF SCOTLAND PLANNING GROUP Breast Cancer Managed Clinical Network Audit Report Breast Cancer Quality Performance Indicators Patients diagnosed during Published: December 2015 Mr Douglas Brown NOSCAN

More information

Ovarian Cancer Quality Performance Indicators (QPI) Comparative Report

Ovarian Cancer Quality Performance Indicators (QPI) Comparative Report SOUTH EAST SCOTLAND CANCER NETWORK (SCAN) PROSPECTIVE CANCER AUDIT Ovarian Cancer Quality Performance Indicators (QPI) Comparative Report Dr Cameron Martin, SCAN Lead Ovarian Cancer Clinician Dr Scott

More information

Audit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed April 2014 March Published: May 2016

Audit Report. Lung Cancer Quality Performance Indicators. Patients diagnosed April 2014 March Published: May 2016 NORTH OF SCOTLAND PLANNING GROUP Lung Cancer Managed Clinical Network Audit Report Lung Cancer Quality Performance Indicators Patients diagnosed April 2014 March 2015 Published: May 2016 Mr Hardy Remmen

More information

Audit Report. Testicular Cancer Quality Performance Indicators. West of Scotland Cancer Network. Urological Cancer Managed Clinical Network

Audit Report. Testicular Cancer Quality Performance Indicators. West of Scotland Cancer Network. Urological Cancer Managed Clinical Network Urological Cancer Managed Clinical Network Audit Report Testicular Cancer Quality Performance Indicators Clinical Audit Data: 01 October 2014 to 30 September 2015 Mr Gren Oades MCN Clinical Lead Tom Kane

More information

IVF Waiting Times Publication

IVF Waiting Times Publication IVF Waiting Times Publication Quarter ending 30 September 2018 Publication date 27 November 2018 An Official Statistics publication for Scotland This is an Official Statistics Publication The Official

More information

Audit Report. Testicular Cancer Quality Performance Indicators. West of Scotland Cancer Network. Urological Cancer Managed Clinical Network

Audit Report. Testicular Cancer Quality Performance Indicators. West of Scotland Cancer Network. Urological Cancer Managed Clinical Network West of Scotland Cancer Network Urological Cancer Managed Clinical Network Audit Report Testicular Cancer Quality Performance Indicators Clinical Audit Data: 01 October 2015 to 30 September 2016 Mr Gren

More information

Activity Report March 2012 February 2013

Activity Report March 2012 February 2013 Lung Cancer Managed Clinical Network Activity Report March 2012 February 2013 John McPhelim Lead Lung Cancer Nurse MCN Clinical Lead Kevin Campbell Network Manager CONTENTS EXECUTIVE SUMMARY 3 1. INTRODUCTION

More information

Audit Report. Colorectal Cancer Quality Performance Indicators. Patients diagnosed April 2014 March Published: July 2016

Audit Report. Colorectal Cancer Quality Performance Indicators. Patients diagnosed April 2014 March Published: July 2016 NORTH OF SCOTLAND PLANNING GROUP Colorectal Cancer Managed Clinical Network Audit Report Colorectal Cancer Quality Performance Indicators Patients diagnosed April 2014 March 2015 Published: July 2016 Mr

More information

Activity Report April 2013 March 2014

Activity Report April 2013 March 2014 North, South East and West of Scotland Cancer Networks Sarcoma National Managed Clinical Network Activity Report April 2013 March 2014 Dr Jeff White Consultant Oncologist NMCN Clinical Lead Lindsay Campbell

More information

Access to Male & Female Sterilisation

Access to Male & Female Sterilisation Access to Male & Female Sterilisation The number of female sterilisation procedures and male vasectomies performed by each NHS board per women and men of reproductive age and the waiting times for these

More information

Report prepared on behalf of the Scottish Head and Neck Cancer Networks by the WoSCAN Information Team

Report prepared on behalf of the Scottish Head and Neck Cancer Networks by the WoSCAN Information Team Scottish Head and Neck Cancer Networks Report of the 2011 Clinical Audit Data Presented at the National Head and Neck Cancer Education Day 26th October 2012 Report prepared on behalf of the Scottish Head

More information

Audit Report. Upper GI Cancer Quality Performance Indicators. Report of the 2016 Clinical Audit Data. West of Scotland Cancer Network

Audit Report. Upper GI Cancer Quality Performance Indicators. Report of the 2016 Clinical Audit Data. West of Scotland Cancer Network Upper Gastro-intestinal Cancer Managed Clinical Network Audit Report Upper GI Cancer Quality Performance Indicators Report of the 216 Clinical Audit Data Mr Matthew Forshaw MCN Clinical Lead Tracey Cole

More information

Audit Report. Colorectal Cancer Quality Performance Indicators. Patients diagnosed April 2016 March Published: March 2018

Audit Report. Colorectal Cancer Quality Performance Indicators. Patients diagnosed April 2016 March Published: March 2018 Colorectal Cancer Managed Clinical Network Audit Report Colorectal Cancer Quality Performance Indicators Patients diagnosed April 2016 March 2017 Published: March 2018 Mr Michael Walker NOSCAN MCN Clinical

More information

Activity Report July 2014 June 2015

Activity Report July 2014 June 2015 West of Scotland Cancer Network Gynaecological Cancer Managed Clinical Network Activity Report July 2014 June 2015 Nadeem Siddiqui Consultant Gynaecological Oncologist MCN Clinical Lead Kevin Campbell

More information

Audit Report. Brain and CNS Cancer Quality Performance Indicators. Report of the 2014 Clinical Audit Data

Audit Report. Brain and CNS Cancer Quality Performance Indicators. Report of the 2014 Clinical Audit Data North, South East and West of Scotland Cancer Networks Neuro-Oncology Cancers Audit Report Brain and CNS Cancer Quality Performance Indicators Report of the 2014 Clinical Audit Data Dr Avinash Kanodia

More information

CANCER IN SCOTLAND: ACTION FOR CHANGE The structure, functions and working relationships of Regional Cancer Advisory Groups

CANCER IN SCOTLAND: ACTION FOR CHANGE The structure, functions and working relationships of Regional Cancer Advisory Groups CANCER IN SCOTLAND: ACTION FOR CHANGE The structure, functions and working relationships of Regional Cancer Advisory Groups Introduction/Background 1. Our National Health: A Plan for action, a plan for

More information

Head and Neck QPI Group Audit Report Head and Neck Quality Performance Indicators Consultant Clinical Oncologist, NHS Grampian

Head and Neck QPI Group Audit Report Head and Neck Quality Performance Indicators Consultant Clinical Oncologist, NHS Grampian Head and Neck QPI Group Audit Report Head and Neck Quality Performance Indicators Patients diagnosed April 2016 March 2017 Published: February 2018 Dr Rafael Moleron Consultant Clinical Oncologist, NHS

More information

Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator

Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator Publication Report Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator Year ending March 2014 Publication date 30 September 2014 A National Statistics Publication for Scotland

More information

ADHD Medication Prescribing in Scotland in 2016/17

ADHD Medication Prescribing in Scotland in 2016/17 ADHD Medication Prescribing in Scotland in 2016/17 Scottish ADHD Coalition Analysis March 2018 www.scottishadhdcoalition.org Notes on data sources Prescribing data was obtained through a data request to

More information

HPV Immunisation Uptake Statistics for the Catch-up Programme

HPV Immunisation Uptake Statistics for the Catch-up Programme Publication Report HPV Immunisation Uptake Statistics for the Catch-up Programme 1 September 2008 31 August 2011 Publication date 25 September 2012 An Official Statistics Publication for Scotland Contents

More information

HPV Immunisation Statistics Scotland

HPV Immunisation Statistics Scotland Publication Report HPV Immunisation Statistics Scotland School Year 2016/17 Publication date 28 November 2017 A National Statistics Publication for Scotland Contents Contents... 1 Introduction... 2 HPV

More information

Activity Report April 2012 March 2013

Activity Report April 2012 March 2013 Gynaecological Cancer Managed Clinical Network Activity Report April 2012 March 2013 Nadeem Siddiqui MCN Clinical Lead Kevin Campbell Network Manager 1 CONTENTS EXECUTIVE SUMMARY 3 1. INTRODUCTION 4 2.

More information

Long Acting Reversible Methods of Contraception (LARC) in Scotland

Long Acting Reversible Methods of Contraception (LARC) in Scotland Publication Report Long Acting Reversible Methods of Contraception (LARC) in Scotland Year ending March 2015 Publication date 3 November 2015 A National Statistics Publication for Scotland Contents Introduction...

More information

Dementia Post- Diagnostic Support

Dementia Post- Diagnostic Support Dementia Post- Diagnostic Support NHS Board Performance 2016/17 Publication date 5 February 2019 A Management Information publication for Scotland This is a Management Information publication Published

More information

Activity Report April 2014 March 2015

Activity Report April 2014 March 2015 North, South East and West of Scotland Cancer Networks Brain/Central Nervous System Tumours National Managed Clinical Network Activity Report April 2014 March 2015 Dr Avinash Kanodia Consultant Radiologist

More information

Dear Colleague. DL (2017) June Additional Funding for CGMs and Adult Insulin Pumps Summary

Dear Colleague. DL (2017) June Additional Funding for CGMs and Adult Insulin Pumps Summary The Scottish Government Healthcare Quality & Improvement Directorate DG Health & Social Care Dear Colleague Additional Funding for CGMs and Adult Insulin Pumps 2017-18 Summary On 7 December 2016, the First

More information

Ovarian Cancer Clinical Quality Performance Indicators

Ovarian Cancer Clinical Quality Performance Indicators Scottish Cancer Taskforce National Cancer Quality Steering Group Ovarian Cancer Clinical Quality Performance Indicators Published: August 2013 Updated: January 2016 (v2.0) May 2018 (v3.0) Published by:

More information

Activity Report April 2012 March 2013

Activity Report April 2012 March 2013 Colorectal Cancer Managed Clinical Network Activity Report April 2012 March 2013 Paul Horgan Professor of Surgery MCN Clinical Lead Kevin Campbell Network Manager 1 CONTENTS EXECUTIVE SUMMARY 3 1. INTRODUCTION

More information

Teenage Booster Immunisation Statistics

Teenage Booster Immunisation Statistics Publication Report Teenage Booster Immunisation Statistics Teenage Td/IPV booster immunisation uptake rates for school years 2011/12 to 2012/13 Publication date 25 March 2014 An Official Statistics Publication

More information

Health & Social Care Research Strategy

Health & Social Care Research Strategy Health & Social Care Research Strategy 2015-2020 http://www.gov.scot/publications/2015/10/5164 The ambition of this strategy is to increase the level of high-quality health research conducted in Scotland,

More information

Activity Report July 2012 June 2013

Activity Report July 2012 June 2013 Urological Cancers Managed Clinical Network Activity Report July 2012 June 2013 Mr Seamus Teahan Consultant Urologist MCN Clinical Lead Tom Kane MCN Manager 1 CONTENTS EXECUTIVE SUMMARY 3 1. INTRODUCTION

More information

Cancer Waiting Times in NHSScotland

Cancer Waiting Times in NHSScotland Publication Report Cancer Waiting Times in NHSScotland 1 July to 30 September 2017 Publication date 12 December 2017 A National Statistics Publication for Scotland Contents Introduction... 3 Main points...

More information

Project Brief. New Cancer Waiting Times. Data Quality Assurance Audit

Project Brief. New Cancer Waiting Times. Data Quality Assurance Audit Project Brief New Cancer Waiting Times Data Quality Assurance Audit Version 1.0 Contents 1 Introduction...3 2 Data Recording and Submitting...4 3 Data Quality Assurance Audit...4 3.1 Areas of Investigation:...4

More information

Cancer Waiting Times in NHSScotland

Cancer Waiting Times in NHSScotland Cancer Waiting Times in NHSScotland 1 October to 31 December 2017 Publication date 27 March 2018 A National Statistics publication for Scotland This is a National Statistics Publication National Statistics

More information

Audit Report Lymphoma Quality Performance Indicators

Audit Report Lymphoma Quality Performance Indicators West of Scotland Cancer Network Haemato-oncology Managed Clinical Network Audit Report Lymphoma Quality Performance Indicators Clinical Audit Data: 01 October 2016 to 30 September 2017 Dr Grant McQuaker

More information

Mental Health Collaborative. Dementia Summary of Activity. October 2009

Mental Health Collaborative. Dementia Summary of Activity. October 2009 Mental Health Collaborative Dementia Summary of Activity October 2009 The following extracts provide either one example of a Board s dementia improvement activity or a brief summary of their current and

More information

Scottish Abdominal Aortic Aneurysm Screening Programme Statistics

Scottish Abdominal Aortic Aneurysm Screening Programme Statistics Scottish Abdominal Aortic Aneurysm Screening Programme Statistics Year ending 31 March 2018 Publication date 5 March 2019 An Official Statistics publication for Scotland This is an Official Statistics

More information

Activity Report March 2013 February 2014

Activity Report March 2013 February 2014 West of Scotland Cancer Network Skin Cancer Managed Clinical Network Activity Report March 2013 February 2014 Dr Girish Gupta Consultant Dermatologist MCN Clinical Lead Tom Kane MCN Manager West of Scotland

More information

Sexually Transmitted Infection, including HIV, Health Protection Scotland Slide Set

Sexually Transmitted Infection, including HIV, Health Protection Scotland Slide Set Sexually Transmitted Infection, including HIV, 213 Health Protection Scotland Slide Set Enhanced surveillance systems are employed to give more detailed information on the epidemiology of infectious syphilis

More information

Audit Report Report of the 2011 Clinical Audit Data

Audit Report Report of the 2011 Clinical Audit Data Lung Cancer Managed Clinical Network Audit Report Report of the 2011 Clinical Audit Data Dr Richard Jones Consultant Clinical Oncologist MCN Clinical Lead Kevin Campbell MCN Manager Julie McMahon Information

More information

Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator

Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator Publication Report Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator Year ending March 2013 Publication date 24 September 2013 A National Statistics Publication for Scotland

More information

HPV Immunisation Statistics Scotland

HPV Immunisation Statistics Scotland HPV Immunisation Statistics Scotland School Year 2017/18 27 November 2018 A National Statistics publication for Scotland This is a National Statistics Publication National Statistics status means that

More information

Audit Report Report of the 2010 Clinical Audit Data

Audit Report Report of the 2010 Clinical Audit Data Gynaecological Cancer Managed Clinical Network Audit Report Report of the Clinical Audit Data Nick Reed Consultant Clinical Oncologist MCN Clinical Lead (Joint) Nadeem Siddiqui Consultant Gynaecological

More information

Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator

Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator Publication Report Long Acting Reversible Methods of Contraception (LARC) Key Clinical Indicator Year ending March 2012 Publication date 25 September 2012 A National Statistics Publication for Scotland

More information

Scottish Bowel Screening Programme Statistics

Scottish Bowel Screening Programme Statistics Publication Report Scottish Bowel Screening Programme Statistics For invitations between 1 November 2013 and 31 October 2015 Publication date 02 August 2016 A National Statistics Publication for Scotland

More information

Audit Report Acute Leukaemia Quality Performance Indicators

Audit Report Acute Leukaemia Quality Performance Indicators Haemato-oncology Managed Clinical Network Audit Report Acute Leukaemia Quality Performance Indicators Clinical Audit Data: 01 July 2014 to 30 June 2017 Dr Mark Drummond Consultant Haematologist MCN Clinical

More information

Audit Report. Bladder Cancer Quality Performance Indicators. West of Scotland Cancer Network. Urological Cancer Managed Clinical Network

Audit Report. Bladder Cancer Quality Performance Indicators. West of Scotland Cancer Network. Urological Cancer Managed Clinical Network Urological Cancer Managed Clinical Network Audit Report Bladder Cancer Quality Performance Indicators Clinical Audit Data: 01 April 2015 to 31 March 2016 Mr Gren Oades MCN Clinical Lead Tom Kane MCN Manager

More information

Scottish Diabetes Survey

Scottish Diabetes Survey Scottish Diabetes Survey 2008 Scottish Diabetes Survey Monitoring Group Foreword The information presented in this 2008 Scottish Diabetes Survey demonstrates a large body of work carried out by health

More information

Cancer Waiting Times in NHSScotland

Cancer Waiting Times in NHSScotland Publication Report Cancer Waiting Times in NHSScotland 1 April to 30 June 2017 Publication date 26 September 2017 A National Statistics Publication for Scotland Contents Introduction... 3 Main points...

More information

Teenage Booster Immunisation Statistics

Teenage Booster Immunisation Statistics Publication Report Teenage Booster Immunisation Statistics Teenage Td/IPV booster and teenage MenC booster immunisation uptake rates for school year 2013/14 Publication date 16 December 2014 An Official

More information

External Assurance of Performance against Cancer Quality Performance Indicators

External Assurance of Performance against Cancer Quality Performance Indicators External Assurance of against Cancer Quality Indicators Lung Cancer August 2017 National Review Healthcare Improvement Scotland is committed to equality. We have assessed the review process for likely

More information

Injecting Equipment Provision in Scotland Survey 2011/12

Injecting Equipment Provision in Scotland Survey 2011/12 Publication Report Injecting Equipment Provision in Scotland Survey 25 June 2013 An Official Statistics Publication for Scotland Contents Introduction... 2 Key points... 3 Results and Commentary... 4 1.

More information

OESOPHAGO-GASTRIC CANCER 2016

OESOPHAGO-GASTRIC CANCER 2016 SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT OESOPHAGO-GASTRIC CANCER 2016 COMPARATIVE AUDIT REPORT Mr Peter Lamb SCAN Lead Upper GI Cancer Clinician Dr Jonathan Fletcher, Consultant Physician,

More information

Scottish Bowel Screening Programme Statistics

Scottish Bowel Screening Programme Statistics Scottish Bowel Screening Programme Statistics For invitations between 1 November 2015 and 31 October 2017 Publication date 07 August 2018 A National Statistics publication for Scotland This is a National

More information

Teenage Booster Immunisation Statistics Scotland

Teenage Booster Immunisation Statistics Scotland Publication Report Teenage Booster Immunisation Statistics Scotland Teenage Td/IPV booster and teenage Men C booster immunisation uptake rates for school year 2014/15 Publication date 15 December 2015

More information

Activity Report July 2014 June 2015

Activity Report July 2014 June 2015 Urological Cancers Managed Clinical Network Activity Report July 2014 June 2015 Mr Gren Oades Consultant Urologist MCN Clinical Lead Tom Kane MCN Manager CONTENTS EXECUTIVE SUMMARY 3 1. INTRODUCTION 5

More information

Annual Report April 2016 March 2017

Annual Report April 2016 March 2017 North, South East and West of Scotland Cancer Networks HepatoPancreatoBiliary Cancers National Managed Clinical Network Annual Report April 2016 March 2017 Professor Stephen Wigmore Consultant Surgeon

More information

Cancer Waiting Times in NHSScotland

Cancer Waiting Times in NHSScotland Cancer Waiting Times in NHSScotland 1 October to 31 December 2018 Publication date 26 March 2019 A National Statistics publication for Scotland This is a National Statistics Publication National Statistics

More information

Mortality amenable to Health Care in Scotland

Mortality amenable to Health Care in Scotland Mortality amenable to Health Care in Scotland 1981-4 Grant I, Munoz-Arroyo R, Oduro S, Whyte B and Fischbacher C Scottish Public Health Observatory Programme Information Services Division June 6 1 Background

More information

abcdefghijklmnopqrstu

abcdefghijklmnopqrstu CMO and Public Health Directorate Health Improvement Strategy Division Dear Colleague Scottish Abdominal Aortic Aneurysm Screening Programme This CEL outlines the plan for the implementation of the AAA

More information

Survey Scottish Diabetes. Survey Monitoring Group

Survey Scottish Diabetes. Survey Monitoring Group Scottish Diabetes Survey 2009 Scottish Diabetes Survey Monitoring Group 2 Foreword The Scottish Diabetes Survey is now in its ninth year. This 2009 Survey, as with previous versions, continues to demonstrate

More information

Audit Report. Bladder Cancer Quality Performance Indicators. Patients diagnosed April 2015 March Published: May 2017

Audit Report. Bladder Cancer Quality Performance Indicators. Patients diagnosed April 2015 March Published: May 2017 Urological Cancer Managed Clinical Network NORTH OF SCOTLAND PLANNING GROUP Audit Report Bladder Cancer Quality Performance Indicators Patients diagnosed April 2015 March 2016 Published: May 2017 Mr Sarfraz

More information

ScotPHO Tobacco Profiles Second release (January 2015)

ScotPHO Tobacco Profiles Second release (January 2015) ScotPHO Tobacco Profiles Second release (January 2015) Salomi Barkat, Shivani Karanwal, Richard Lawder, Anna MacKinnon, Diane Stockton (ISD Scotland) and Fiona Moore (NHS Health Scotland) Contents Background...

More information

Activity Report April June 2012

Activity Report April June 2012 Urological Cancers Managed Clinical Network Activity Report April 2011- June 2012 Mr Seamus Teahan Consultant Urologist MCN Clinical Lead Tom Kane MCN Manager CONTENTS EXECUTIVE SUMMARY 3 1. INTRODUCTION

More information

Peripheral Arterial Disease

Peripheral Arterial Disease Scottish Needs Assessment Programme SNAP Briefing Peripheral Arterial Disease Office for Public Health in Scotland 1 Lilybank Gardens Glasgow G12 8RZ Tel - 0141 330 5607 Fax - 0141 330 3687 1 PREFACE This

More information

Audit Report Report of the 2012 Clinical Audit Data

Audit Report Report of the 2012 Clinical Audit Data Urological Cancer Managed Clinical Network Audit Report Report of the 2012 Clinical Audit Data Mr Seamus Teahan MCN Clinical Lead Tom Kane MCN Manager Sandie Ker Information Officer Urological Cancer Audit

More information

Child Health Month Review Statistics

Child Health Month Review Statistics Publication Report Child Health 27-30 Month Review Statistics Scotland 2015/16 Publication date 7 February 2017 An Official Statistics Publication for Scotland Contents Introduction... 2 Methods and Definitions...

More information

COLORECTAL CANCER Quality Performance Indicators (QPI) Comparative Report

COLORECTAL CANCER Quality Performance Indicators (QPI) Comparative Report SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT COLORECTAL CANCER 2016 2017 Quality Performance Indicators (QPI) Comparative Report Mr S Yalamarthi, NHS Fife, Lead Colorectal Cancer Clinician,

More information

National Naloxone Programme Scotland

National Naloxone Programme Scotland National Naloxone Programme Scotland Monitoring Report 2017/18 27 November 2018 An Official Statistics publication for Scotland This is an Official Statistics Publication The Official Statistics (Scotland)

More information

Scottish Diabetes Survey 2012

Scottish Diabetes Survey 2012 Scottish Diabetes Survey 2012 Scottish Diabetes Survey Monitoring Group 1 Scottish Diabetes Survey Monitoring Group Contents Foreword... 3 Executive Summary... 5 Prevalence... 6 Undiagnosed diabetes...

More information

Primary 1 Body Mass Index (BMI) Statistics

Primary 1 Body Mass Index (BMI) Statistics Publication Report Primary 1 Body Mass Index (BMI) Statistics School Year 2010/11 Publication date 24 April 2012 A National Statistics Publication for Scotland Contents Contents... 1 About ISD... 2 Official

More information

Scotland s Sexual Health Information, SSHI Health Protection Scotland Slide Set

Scotland s Sexual Health Information, SSHI Health Protection Scotland Slide Set Scotland s Sexual Health Information, SSHI 21 Health Protection Scotland Slide Set Data on positive diagnoses of selected STIs, including HIV, are reported from all microbiological laboratories throughout

More information

National Drug and Alcohol Treatment Waiting Times

National Drug and Alcohol Treatment Waiting Times National Drug and Alcohol Treatment Waiting Times 1 October 31 December 2017 Publication date 27 March 2018 A National Statistics publication for Scotland This is a National Statistics Publication National

More information

Audit Report. Report of the 2010 Clinical Audit Data. West of Scotland Cancer Network. Lung Cancer Managed Clinical Network

Audit Report. Report of the 2010 Clinical Audit Data. West of Scotland Cancer Network. Lung Cancer Managed Clinical Network West of Scotland Cancer Network Lung Cancer Managed Clinical Network Audit Report Report of the 2010 Clinical Audit Data Dr Richard Jones Consultant Clinical Oncologist MCN Clinical Lead Tracey Cole MCN

More information

Mental Health Collaborative. Dementia Summary of Activity. April 2010

Mental Health Collaborative. Dementia Summary of Activity. April 2010 Mental Health Collaborative Dementia Summary of Activity April 2010 The following extracts provide either one example of a Board s dementia improvement activity or a brief summary of a Board s current

More information

Colorectal Cancer Comparative Audit Report

Colorectal Cancer Comparative Audit Report SOUTH EAST SCOTLAND CANCER NETWORK (SCAN) PROSPECTIVE CANCER AUDIT Colorectal Cancer 2014 2015 Comparative Audit Report Mr B.J. Mander, NHS Lothian, Lead Colorectal Cancer Clinician, SCAN Group Chair Mr

More information

Health Protection Scotland

Health Protection Scotland Quarterly epidemiological data on Clostridium difficile infection, Escherichia coli bacteraemia, Staphylococcus aureus bacteraemia and Surgical Site Infection in Scotland. October to December 2017 Publication

More information

National Drug and Alcohol Treatment Waiting Times

National Drug and Alcohol Treatment Waiting Times National Drug and Alcohol Treatment Waiting Times 1 April 30 June 2018 Publication date 25 September 2018 A National Statistics publication for Scotland This is a National Statistics Publication National

More information